RhoA GTPase-Induced Ocular Hypertension in a Rodent Model Is Associated with Increased Fibrogenic Activity in the Trabecular Meshwork  by Pattabiraman, Padmanabhan P. et al.
The American Journal of Pathology, Vol. 185, No. 2, February 2015MATRIX PATHOBIOLOGY
ajp.amjpathol.orgRhoA GTPase-Induced Ocular Hypertension in a
Rodent Model Is Associated with Increased
Fibrogenic Activity in the Trabecular Meshwork
Padmanabhan P. Pattabiraman,* Tommy Rinkoski,y Eric Poeschla,y Alan Proia,z Pratap Challa,* and Ponugoti V. Rao*xFrom the Departments of Ophthalmology,* Pathology,z and Pharmacology and Cancer Biology,x Duke University School of Medicine, Durham, North
Carolina; and the Department of Molecular Medicine,y Mayo Clinic College of Medicine, Rochester, MinnesotaAccepted for publicationC
P
hOctober 7, 2014.
Address correspondence to
Ponugoti V. Rao, Ph.D., Duke
Eye Center, 2351 Erwin Rd.,
Durham, NC 27710.
E-mail: p.rao@dm.duke.edu.opyright ª 2015 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2014.10.023Ocular hypertension arising from increased resistance to aqueous humor (AH) outﬂow through the
trabecular meshwork is a primary risk factor for open-angle glaucoma, a leading cause of blindness.
Ongoing efforts have found little about the molecular and cellular bases of increased resistance to AH
outﬂow through the trabecular meshwork in ocular hypertension patients. To test the hypothesis that
dysregulated Rho GTPase signaling and a resulting ﬁbrotic activity within the trabecular meshwork may
result in ocular hypertension, we investigated the effects of expressing a constitutively active RhoA
GTPase (RhoAV14) in the AH outﬂow pathway in Sprague-Dawley rats by using lentiviral vector-based
gene delivery. Rats expressing RhoAV14 in the iridocorneal angle exhibited a signiﬁcantly elevated
intraocular pressure. Elevated intraocular pressure in the RhoAV14-expressing rats was associated with
ﬁbrotic trabecular meshwork and increased levels of F-actin, phosphorylated myosin light chain,
a-smooth muscle actin, collagen-1A, and total collagen in the trabecular AH outﬂow pathway. Most of
these changes were ameliorated by topical application of Rho kinase inhibitor. Human autopsy eyes
from patients with glaucoma exhibited signiﬁcant increases in levels of collagen-1A and total collagen
in the trabecular AH outﬂow pathway. Collectively, these observations indicate that increased ﬁbro-
genic activity because of dysregulated RhoA GTPase activity in the trabecular AH outﬂow pathway
increases intraocular pressure in a Rho kinase-dependent manner. (Am J Pathol 2015, 185: 496e512;
http://dx.doi.org/10.1016/j.ajpath.2014.10.023)Supported by NIH grant R01EY18590 (P.V.R.).
Disclosures: P.C. and P.V.R. have stock ownership in Aerie Pharma-
ceuticals, which is developing Rho kinase inhibitors for glaucoma treat-
ment. The other authors declare no conﬂicts of interest.Glaucoma, the second leading cause of blindness in the
United States is an optic nerve degenerative disease with
characteristic optic disk and visual ﬁeld changes.1 Primary
open-angle glaucoma (POAG), a prevalent form of the dis-
order, is commonly associated with elevated intraocular
pressure (IOP) or ocular hypertension (OHT), with increased
IOP being a deﬁnite and primary risk factor for POAG.2,3
Importantly, the risk of developing glaucoma decreases
signiﬁcantly when 20% reduction in IOP is achieved in pa-
tients with OHT,4,5 and ocular hypotensive therapy remains
the mainstay of treatment for glaucoma.3,6 Elevated IOP
derives primarily from increased resistance to aqueous humor
(AH) outﬂow, especially through the conventional or
trabecular pathway, consisting of trabecular meshwork (TM),
Schlemm canal (SC), and the juxtacanalicular connective
tissue (JCT).7e11stigative Pathology.
.The TM is a unique structure consisting of highly porous
beams of collagen covered by endothelial-like cells with
extracellular material occupying the spaces between the
beams. The JCT region between the TM and SC is comprised
of cells embedded in extracellular matrix (ECM) with
myoﬁbroblast-like features.10 SC is a continuous endothelial
lined canal that drains AH into the collecting channels and
aqueous veins.10 The TM from glaucomatous eyes has been
found to exhibit alterations in ECM organization and
turnover8,10,12,13 and to accumulate sheath-like plaque
material.14,15 It is widely believed that biomechanical
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deposition and turnover in the JCT and basement membrane
of the inner wall of the SC could lead to increased resistance
to AH outﬂow and elevated IOP.8,16,17 However, little is
known about the origin and activation of matrix-producing
cells and their role in ECM deposition and turnover and in
resistance to AH outﬂow in both normal and glaucomatous
eyes.8,18
We and others have identiﬁed the ability of various
physiologic agents, including bioactive lipids (lysophosha-
tidic acid and sphingosine-1-phosphate),19 endothelin-1,20
transforming growth factor (TGF)-b2,21 connective tissue
growth factor (CTGF),22,23 and autotaxin,24 the levels of
some of which are known to be elevated in the AH of glau-
coma patients,24e27 to regulate AH outﬂow resistance via
activation of the Rho/Rho kinase signaling pathway. Most
signiﬁcantly, and in contrast to the effects of Rho kinase and
Rho GTPase inhibitors,28 activation of RhoA signaling in
organ-cultured porcine eyes resulted in decreased AH
outﬂow facility,29 leading us to explore the cellular and
molecular bases for the increased resistance to AH outﬂow
elicited by activation of Rho GTPase. Moreover, our recent
studies found that TM cells expressing a constitutively active
RhoA GTPase (RhoAV14) or treatment of human TM cells
with TGF-b2, CTGF, or lysophoshatidic acid led to increased
production of not only ECM (collagen-1A, tenascin-C,
ﬁbronectin, and laminin) proteins, cytokines, and a-smooth
muscle actin (a-SMA)21,22,29 but importantly also induced
the expression of ﬁbroblast-speciﬁc protein-1 (also known as
S100A4), a-SMA, and regulators of epithelial/endothelial to
mesenchymal transition, including serum response factor,
myocardin-related transcription factor, slug and twist in a
Rho kinase-dependent manner to indicate the propensity of
TM cells for transdifferentiating into myoﬁbroblast-
like a-SMA and collagen-1Aeexpressing contractile
cells.21,30,31 Furthermore, glaucoma patients are reported to
have elevated levels of Rho GTPase in the optic nerve head,
suggesting plausible involvement of the Rho GTPase
signaling pathway in glaucoma pathobiology.32,33 Signiﬁ-
cantly, dysregulation of Rho/Rho kinase signaling is
conﬁrmed to be involved in pathophysiology of various
diseases, including cardiac, neurologic, kidney, pulmonary,
and ﬁbrotic diseases and cancer.34e39
The activated, GTP-bound form of Rho GTPase works in
concert with its downstream effector Rho kinase, which is a
serine-threonine kinase, to regulate various cellular pro-
cesses, including cellular contraction, migration, polarity,
adhesion, and transcription by controlling actin cytoskeletal
dynamics, myosin II activity, and cell adhesive inter-
actions.40e43 Further, it is now well recognized that the Rho
GTPase/Rho kinase signaling pathway not only controls AH
outﬂow through the TM in perfused eyes but also affects IOP
in different animal models and humans.20,44e50 Importantly,
these consistent observations have prompted several ongoing
phase 2/3 human clinical trials to investigate the use of Rho
kinase inhibitors for lowering IOP and treatment ofThe American Journal of Pathology - ajp.amjpathol.orgglaucoma.46,51 However, the cellular and molecular bases for
ocular hypotensive activity of Rho kinase inhibitors is not
thoroughly understood. Therefore, in this study we have
explored the in vivo effects of constitutively activated RhoA
GTPase on IOP in rats and on the ﬁbrogenic response in the
trabecular AH outﬂow pathway. In addition, we evaluated the
proﬁles of collagen-1A and total collagen expression in the
AH outﬂow pathway of human glaucoma specimens along
with age-matched nonglaucoma human eyes.
Materials and Methods
Lentivirus Vector Production and Puriﬁcation
Human RhoA G14V mutant (RhoAV14) was ampliﬁed by
PCR from a pcDNA 3.1 plasmid (obtained from Dr. Patrick
Casey, Duke University, Durham, NC), cloned into a HIV-
based bicistronic lentiviral vector TSIN-green ﬂuorescent
protein (GFP).52 The vector allowed simultaneous expression
of RhoAV14 and GFP and was puriﬁed by using the endo-
toxin free maxiprep kit (Qiagen Sciences, Germantown,
MD). Vesicular stomatitis virus glycoprotein Gepseudotyped
HIV vectors were generated with packaging plasmids that
expressed constitutively active RhoAV14-GFP as we
described earlier.53 A lentiviral vector expressing GFP alone
was prepared and puriﬁed for use as a control. Brieﬂy,
RhoAV14-expressing transfer construct along with pack-
aging construct (CMVdR8.91) and the envelope plasmid
[pMD.G (vesicular stomatitis virus glycoprotein G)] mixed in
the ratio of 3:3:1 was used to transfect human embryonic
kidney 293T cells by using calcium phosphate transfection.
The transfection protocol included treatment of cells with the
plasmid DNA of interest, 0.01 mol/L Tris pH 8.0, 2.5 mol/L
calcium chloride, and 2 HEPES-buffered saline for a period
of 16 hours. Transfection mix was subsequently replaced
with fresh cell culture media, and 48 hours later vector was
harvested by ﬁltering cell culture conditioned media through
a 0.45-mm low protein-binding ﬁlter (Millex-HV; Millipore,
Cork, Ireland). Supernatant was then concentrated with two
rounds of ultracentrifugation, with the second round using a
sucrose gradient, and the viral pellet was resuspended in
phosphate-buffered saline (PBS). Human embryonic kidney
293T cells were transduced with the vector, and the potency
was determined with ﬂow cytometric analysis by using the
reporter gene GFP in human embryonic kidney 293T cells.53
Animals
Sprague-Dawley female rats (176 to 200 g of weight and
aged >60 days) were purchased from Charles River Labo-
ratories (Wilmington, MA) and housed under a standard
12-hour light and dark cycle with food and water provided
ad libitum. All animal procedures were approved by the
Institutional Animal Care and Use Committee at the Duke
University Medical Center and conducted in accordance
with the Declaration of Helsinki. To test the effects of497
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divided into three groups: with group I (nZ 26) and group
II (n Z 27) serving as controls and receiving either an in-
jection of 10 mL of PBS or GFP-expressing vector [10 mL,
titer of 1  107 transduction units (TUs)/mL)], respectively.
The rats in group III (n Z 27) received the RhoAV14-
GFPeexpressing vector (10 mL, titer of 1  107 TU/mL).
Injections were administered only to the right eye of each
rat, whereas the left eye served as the untreated control. The
experiments were performed in three independent sets, with
Set-1 having 8 rats in each group, Set-2 having 12 rats in
each group, and Set-3 having 6 rats in the saline- and 7 in
the GFP and RhoAV14-injected groups. Set-3 was used to
evaluate the effects of Rho kinase inhibitor on IOP in the
RhoAV14-expressing rats.
Intracameral Injections
Rats were anesthetized with i.p. injection of ketamine/xyla-
zine at 60 mg per 8 mg/kg body weight. Before administering
intracameral injections, the cornea was treated with a drop of
topical anesthetic (0.05% proparacaine hydrochloride
ophthalmic solution; Akorn Inc., Lake Forest, IL). Intra-
cameral lentiviral vector delivery was performed under an
operating microscope, using a 33-gauge needle Hamilton
syringe (Hamilton, Reno, NV). Ten microliter of viral vector
prep that expressed either GFP or RhoAV14/GFP was
injected into the right eye of rats with the needle inserted
through the superior cornea at the limbus with the bevel up, to
gently reach the center of the anterior chamber. During this
process of needle insertion, approximately 10 mL of AH was
released to avoid generating high IOP immediately after
intracameral injection. When the needle was inside the
anterior chamber, the sample was delivered with a gentle
push for >30 seconds, and the ﬂuid entry was monitored by
direct visualization through the operating microscope. The
needle was left in place for at least 2 minutes and was
withdrawn gradually to minimize AH leakage. Rats were
returned to their cages after they were fully awake.
IOP Detection
At the beginning of the study, basal IOPs were recorded in
rats by using a Tonolab (iCare Laboratory, Espoo, Finland)
after mild sedation with ketamine/xylazine. After injection
with saline or lentiviral vectors, IOPs were recorded in
both the eyes of sedated rats in a blinded fashion, once
every 3 to 4 weeks for the next 5 months (155 days). For
IOP measurements, rats were positioned with the visual
axis horizontal to the probe, and ﬁve consecutive readings
(units that correlate to IOP) were obtained. For the Rho
kinase inhibitor study, IOP was measured between 1 and
1.5 hours after topical application of Y27632 [Rho kinase
inhibitor; (R)-(þ)-trans-N-(4-Pyridyl)-4-(1-aminoethyl)-
cyclohexanecarboxamide dihydrochloride; Tocris Biosci-
ence, Minneapolis, MN]. Day-time IOP recordings were498recorded between 10 AM and 1 PM, and night-time re-
cordings were acquired between 10 PM and 1 AM.
Y27632 was reconstituted in PBS (pH 7.4). For evalu-
ating the effects of topical application of this inhibitor, two
4-mL drops of Y27632 at a concentration of 10 mmol/L
were applied to eyes (right) that had been intracamerally
injected with saline, GFP, or RhoAV14/GFP-expressing
viral vector particles, approximately for 5 months after the
injection. The left eye (uninjected) of each rat received
vehicle control (PBS). Topical administration of Rho kinase
inhibitor to the central cornea was performed at 30-second
intervals with the eyelids retracted to prevent blinking. Drug
application was done every day in the morning between 10
AM and 12 PM for 15 days consecutively.
Tissue Processing
Rats were sacriﬁced on completion of the IOP studies by
anesthetization with ketamine/xylazine and transcardially fol-
lowed by perfusion with PBS and ﬁxation with 4% para-
formaldehyde in PBS. The eyes were enucleated, and tiny
incisionswere made to the cornea to enable entry of the ﬁxative
(2.5% glutaraldehyde and 2% formaldehyde for electron mi-
croscopy studies) into the anterior chamber. For parafﬁn
embedding, enucleated eyes were formalin-ﬁxed (3.7%
neutral-buffered formalin), processed on an automatic tissue
processor, followed by parafﬁn embedding and tissue
sectioning (5-mm sections) with the use of core services offered
by the Pathology Department, Duke University. For cry-
osections, enucleated eyes were ﬁxed in 4% paraformaldehyde
in PBS (pH 7.4) at 4C for 18 hours and transferred sequen-
tially into 5% and 30% sucrose in the same buffer, each at 4C
overnight. Eye anterior segment cryosections (5 mm) were
obtained with a cryostat (Microm HM 550) and mounted on
gelatin-coated slides as described earlier by us.29
Electron Microscopy and Immunogold Labeling
The glutaraldehyde and formaldehyde-ﬁxed eyes were
bisected at the equator, and the anterior segments were cut
into four quadrants. Semithin sections of eye anterior seg-
ments (0.5 mm) were stained with toluidine blue and were
visualized by light microscopy. For transmission electron
microscopy (TEM), tissue specimens were ﬁxed with 1.0%
osmium tetroxide in 0.1 mol/L sodium cacodylate buffer
and were stained with 1% uranyl acetate. Finally, 70-nm-
thick microtome sections were stained with KMnO4 and
Sato stain and were photographed with TEM (JEM-1400;
JEOL USA, Peabody, MA) as we described previously.45
For immunologic electron microscopy, tissue samples
were ﬁxed with 2% to 4% paraformaldehyde in 0.1 mol/L
phosphate buffer, dehydrated through a graded series of
ethyl alcohols, and embedded in Unicryl (Vector Labora-
tories, Burlingame, CA). Thin sections (70- to 90-nm thick)
were mounted on Formvar/carbon-coated nickel grids. After
drying, the grids were ﬂoated on drops of 50 mmol/Lajp.amjpathol.org - The American Journal of Pathology
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rinsing with PBS, the grids were then placed into the
blocking buffer for a block/permeabilization step of 30 to 45
minutes. The grids were then placed in the primary antibody
(collagen-1A) overnight at 4C, rinsed with the incubation
buffer, and ﬂoated on drops of the secondary antibody with
attached 6-mm gold particles for 2 hours at room tempera-
ture as we described earlier.54 After rinsing with a rinse
buffer (incubation buffer without Tween 20), the grids were
placed in 2.5% glutaraldehyde in 0.1 mol/L phosphate
buffer for 5 minutes. Finally, the tissue specimens were
imaged with JEM-1400 TEM (JEOL USA).
Human Specimens
Formalin-ﬁxed, parafﬁn-embedded human eyes from patients
with or without glaucoma were prepared as part of the routine,
complete autopsies at Duke University Medical Center.
Electronic and paper medical records of autopsy specimens
were used to identify patient age, sex, race, ocular diseases,
systemic diseases, ocular medications, and systemic medica-
tions as described earlier by us.32 Sample use for research was
done after approval from the Duke University Medical Center
Institutional Review Board. Ten eyes from 10 patients with a
history of glaucoma or typical histologic evidence of POAG
and 10 eyes from 10 age-matched nonglaucoma (control)
patients were analyzed. The demographic details of human
specimens used in this study are provided in Supplemental
Table S1. IOP readings and visual ﬁeld scores were not
available for any of these patients.
Immunohistochemistry
For both rat and human parafﬁn-embedded sections, a stan-
dard tissue immunohistochemistry protocol was followed as
we described earlier.32 Brieﬂy, 5-mm-thick tissue sections
were deparafﬁnized and rehydrated with three changes of
xylene, followed by three changes of absolute ethyl alcohol,
and washed with three changes of water. To unmask the
antigen epitopes, heat-induced antigen retrieval was per-
formed with 0.1 mol/L sodium citrate buffer pH 6.0 (Vector
Laboratories) for 20 minutes at 100C. The slides were then
rinsed in water and washed two times with 1 Tris-buffered
saline (10 mmol/L Tris and 100 mmol/L NaCl; Tris-buffered
saline). Nonspeciﬁc staining was blocked with Sniper
Background Reducer (Biocare Medical, Concord, CA). The
tissue sections were incubated with primary antibody over-
night at 4C in a humidiﬁed chamber. All primary antibodies
were diluted in 1% bovine albumin (fatty acid free and low
endotoxin) that contained Tris-buffered saline and were used
at a 1:50 dilution. Polyclonal anti-rabbit collagen-1A
(Abcam, Cambridge, MA) and a-SMA (Sigma-Aldrich, St.
Louis, MO) antibodies were used. After incubation, the slides
were washed with Tris-buffered saline three times and
stained uniformly. To stain normal and glaucomatous human
specimens simultaneously, we split our subject populationThe American Journal of Pathology - ajp.amjpathol.orginto two groups, with each group containing a mixture of
both normal and glaucoma specimens. All eyes were
assigned a numeric code so investigators were masked to
sample identity. All tissue specimens were stained in dupli-
cate on different days, and a negative control (without pri-
mary antibody) was run for each assay. Detection of mouse
primary antibody binding was done with Polylink-2 AP Plus
Mouse NR Detection system and Permanent Red Kit for
Immunochemistry (GBI Labs, Mukilteo, WA). Detection of
rabbit primary antibody binding was done with Mach 4
Universal AP Polymer Kit (Biocare Medicals, Concord, CA)
in combination with Vulcan Fast Red chromogen (Biocare
Medicals) according to the manufacturer’s protocol. The
sections were counterstained with hematoxylin and were
rinsed with deionized water. The tissue sections were pro-
tected with a covereslip with the use of Permount mounting
medium (Fisher Scientiﬁc, Waltham, MA). Slides were
viewed and graded with a Zeiss Axioplan 2 microscope (Carl
Zeiss GmbH, Jena, Germany), and images were captured
with an Olympus Vanox microscope (Olympus America,
Center Valley, PA).
Interpretation of immunohistochemistry results was per-
formed as described in our previous work with minor
modiﬁcations.32 For the rat and human specimens, two
(P.P.P. and P.V.R.) and three reviewers (P.P.P., A.P., and
P.V.R.), respectively, independently scored immunostaining
intensity of AH outﬂow pathway tissues. The slides were
masked such that the reviewers were unaware of which
samples were from saline-, GFP-, or RhoAV14-injected
eyes in the rat study or which specimens were derived
from control versus glaucoma patients in the human study.
In the case of human samples, to minimize scoring bias
because of recognition of eyes with glaucomatous damage
to the optic nerve/retina, the observers focused their atten-
tion on the anterior chamber angle. The reviewers scored the
uveoscleral (US)-TM, corneoscleral (CS)-TM, and JCT and
SC on both the nasal and temporal side of each globe for the
human eyes as we described earlier.32 In the case of rat eyes,
the scoring was done on the TM region (without dis-
tinguishing them into CS or US and JCT) and SC region
because the JCT region was not distinguishable from TM in
many samples. Staining intensity was scored from 0 (no
staining) to 5 (most intense staining) as described in our
earlier work.32 Any of the regions that were not scored by at
least two of the three reviewers were omitted from analysis;
this was usually because of a reviewer being concerned
about possible artifactual presence or absence of staining
throughout the section or sectioning anomalies such as folds
or tears. The score was excluded from analysis if there was
more than a two-point discrepancy between grading by
the reviewers. After all reviewers had scored the slides, the
code was broken. The scores from the nasal and temporal
sides of the outﬂow tract in each eye were pooled, and
values for the duplicate slides were averaged to accommo-
date for the small variability inherent in immunohisto-
chemical staining.499
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For F-actin staining, preblocked rat eye tissue cryosections
were labeled with tetra-rhodamine isothiocyanateeconjugated
phalloidin (500 ng/mL; Sigma-Aldrich) as we described
earlier.21 For phosphorylated myosin light chain (pMLC),
air-dried rat eye tissue cryosections were blocked and
immunostained with polyclonal antibody to pMLC (Cell
Signaling Technologies, Danvers, MA), at a dilution of
1:50. After incubation with primary antibody, slides were
washed and incubated in the dark for 2 hours at room
temperature, with Alexa Fluor 568-conjugated secondary
antibody (Invitrogen, Carlsbad, CA), as we described
earlier.30 Slides were mounted with Vector mount and
nail polish and were photographed with a Nikon Eclipse
90i confocal laser scanning microscope (Nikon, Mell-
ville, NY).
Sirius Red stain, a strong anionic dye, was used for
collagen detection.55 Tissue sections (rats or human) were
deparafﬁnized and hydrated via a descending ethanol series
(100%, 95%, 80%, and 70%), followed by two washes in
distilled water. The specimens were then immersed in Sirius
Red solution (0.1% in saturated picric acid) for 60 minutes
for rat sections and 90 minutes for human sections. The
sections were rinsed with running tap water for exactly 3
minutes and subsequently with acidiﬁed water, followed by
dehydration and mounted with Permount mounting medium
(Fisher Scientiﬁc). Stained sections were graded with a
Zeiss Axioplan 2 microscope (Carl Zeiss GmbH), and im-
ages were captured with an Olympus Vanox microscope
(Olympus America).
Cell Cultures
Human TM (HTM) cells were cultured from TM tissue
isolated from leftover donor corneal rings after they had
been used for corneal transplantation at the Duke
Ophthalmology Clinical Service as described previously.21
HTM cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium that contained 10% fetal bovine serum and 100
U/500 mL penicillin, 100 mg/500 mL streptomycin, and 4
mmol/L glutamine. All cell culture experiments were
conducted with conﬂuent cultures (derived from passages
between four and six times) that were serum starved for at
least 24 hours unless mentioned otherwise. HTM cells
were grown on gelatin-coated coverslips or tissue culture
plates to 70% to 80% conﬂuence and were infected with
lentiviral vectors that expressed either GFP or RhoAV14/
GFP at 1  107 TU/mL for a 10-cm plate. After 36 hours,
virus media were removed and replaced with normal
Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% fetal bovine serum and observed for the GFP
expression. GFP expression was seen within 4 to 6 days.
At this point, cells were serum starved for 48 hours, and
they were ﬁxed for immunostaining, or cell lysates were
prepared for immunoblotting.500Immunoblot Analysis
The cell lysates derived from HTM cells that expressed
RhoAV14/GFP or GFP alone were immunoblotted for total
RhoA, GFP, pMLC, phosphorylated-myosin phosphatase tar-
geting subunit (pMYTP1), a-SMA, and b-actin with the use of
the respective polyclonal (RhoA from Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA; GFP from BD Biosciences, San
Jose, CA; pMLC from Cell Signaling Technologies; and
pMYPT1 from Millipore, Billerica, MA) or monoclonal (a-
SMA and b-actin from Sigma-Aldrich) primary antibodies in
conjunction with relevant secondary antibodies as described
earlier.21,30 Immunoblots were developed by enhanced chem-
iluminescence and were scanned densitometrically with a Gel
Doc scanner (FOTODYNE Inc., Hartland, WI) equipped with
TL100 software. Densitometry analyses were performed with
ImageJ software version 1.46 (NIH, Bethesda, MD).
Statistical Analysis
Analysis of variance was performed to test IOP changes
between saline-, GFP-, and RhoAV14-injected groups. If the
test proved signiﬁcant, independent groups were assessed for
signiﬁcance by using the nonparametric Wilcoxon rank sum
test. The nonparametric Wilcoxon rank sum test of differ-
ences in medians was performed to compare ﬁnal scores for
both rat and human samples by region and stain. The cell
culture-based experiments were analyzed with Student’s
t-test, with P < 0.05 being statistically signiﬁcant.
Results
RhoAV14 Induces Changes in Actin Cytoskeletal
Organization and Contractile Properties in the HTM
Cells
Before testing the effects of RhoAV14 expression on IOP in
live rats, we assessed the effectiveness of the lentiviral vector
that we generated for expressing RhoAV14 and GFP in
cultured HTM cells. We monitored GFP expression, changes
in actin cytoskeletal organization, and phosphorylation status
of MYPT1 and MLC which regulate cellular contraction
induced via the activated Rho/Rho kinase signaling pathway.
Figure 1A depicts the gene map of the lentiviral transfer vec-
tor. Virus titers were in the range of 3.6  1.2  107 TU/mL
and 3.0  0.58  107 TU/mL for GFP and RhoAV14 GFP,
respectively (means SD of three independent preparations).
The titers were adjusted to 1  107 TU/mL and used to infect
HTM cells in cultures. GFP expression was noted in HTM
cells 4 days after transduction (Figure 1B). Cells were then
serum starved for 48 hours before analysis of changes in cell
morphology. As expected, RhoAV14-expressing cells
exhibited either a rounded or contractile (or stiffened)
morphology on the basis of phase-contrast images and
compared with the GFP-expressing control cells (not shown).
In addition, the RhoAV14-expressing HTM cells showed aajp.amjpathol.org - The American Journal of Pathology
Figure 1 RhoAV14-induced effects on cell morphology, F-actin, and contractile activity in cultured HTM cells. A: Map of bicistronic transfer construct
depicting the RhoAV14-IRES-GFP insert and the CMV promoter that allows simultaneous expression of RhoAV14 and GFP from the same mRNA transcript.
B: Four days after viral vector treatment, HTM cells expressing either RhoAV14/GFP or GFP alone were serum starved for 48 hours. HTM cells expressing
RhoAV14/GFP exhibit a stiffened and contractile (rounding) cell morphology compared with the ﬂattened and elongated morphology seen in GFP-expressing
control cells. RhoAV14-expressing cells also display increased actin stress ﬁbers (stained with rhodamine-phalloidin) compared with the GFP-expressing control
cells. Representative images are shown to depict these changes. C: Under the conditions described above, immunobloting analyses of HTM cells reveals similar
levels of GFP in both GFP-expressing and RhoAV14/GFP-expressing cells, conﬁrming the expression of recombinant proteins. In addition, RhoAV14-expressing
HTM cells show a signiﬁcant increase in the levels of total RhoA, pMYPT1, pMLC, and a-SMA compared with GFP-expressing control HTM cells. b-actin served as
a loading control. D: Histograms show quantitative changes that are based on densitometric analysis of immunoblots for RhoA, pMYPT1, pMLC, and a-SMA
normalized against b-actin between the GFP control and RhoAV14-expressing cells. Values are expressed as means  SD. n Z 3 independent specimens.
*P < 0.05. Scale bar Z 50 mm. ampR, ampicillin resistance; CMV, cytomegalovirus; eGFP, enhanced green ﬂuorescent protein; HTM, human trabecular
meshwork; IRES, internal ribosome entry site; pMLC, phosphorylated myosin light chain; pMYPT1, phosphorylated-myosin phosphatase targeting subunit;
polyA, polyadenylic acid; RhoAV14, constitutively active RhoA GTPase; a-SMA, a-smooth muscle actin; SV40, simian virus 40.
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rhodamine-phalloidin ﬂuorescence (Figure 1B), and they also
exhibited signiﬁcant increases in the levels of total RhoA,
a-SMA, pMYPT1, and MLC relative to the GFP-expressing
control cells (Figure 1, C and D). GFP expression was also
conﬁrmed by immunoblot analysis in both the controls (treated
with GFP-expressing vector) and RhoAV14-expressing cells
(treated with the RhoAV14 and GFP-expressing vector).
These cell-based observations conﬁrm the suitability of lenti-
viral vector to drive expression of the two transgenes in HTM
cells and the activated state of the expressed recombinant
RhoAV14 GTPase.
Expression of RhoAV14 in the Iridocorneal Angle of
Rats Leads to OHT
To determine the role of Rho GTPase activity in regulation of
IOP in live rats, we evaluated the effects of expressing
RhoAV14 in the trabecular AH outﬂow pathway of rats on
IOP. For this study, adult Sprague-Dawley female rats were
divided into three groups with group I and group II serving as
controls that received either a 10-mL saline injection or 10 mL
of 1  107 TU/mL GFP-expressing lentviral vector, respec-
tively. The rats in group III received 10 mL of RhoAV14/GFP-
expressing vector at a titer of 1  107 TU/mL. Only one eye
(right) of each rat from all three groups received intracameral
injections, and the contralateral eyes were untreated. A total of
20 rats from each group (Set-1, nZ 8; Set-2, nZ 12) received
a single intracameral injection of saline or vector that expressed
GFP or RhoAV14/GFP. Basal IOPs were measured in all rats a
few days before the intracameral injections, and IOP recording
under sedation was continued after injection, once every 3 to 4
weeks for>22 weeks, using a Tonolab (iCare Laboratory). InThe American Journal of Pathology - ajp.amjpathol.orgthe Set-1 and Set-2 rats that expressed RhoAV14/GFP, we
recorded a signiﬁcant increase in IOP at 68 and 94 days after
injection, respectively, compared with the GFP-expressing and
saline-injected control rats (Figure 2). IOP values in the Set-1
RhoAV14-expressing rat eyes were found to be 12.07  0.7
mm Hg (means  SEM; n Z 8) and signiﬁcantly higher
(P< 0.01) than in the saline-injected (10.1 0.8 mm Hg) and
GFP-expressing control (9.9  0.6 mm Hg) rats. Similarly,
IOP values in the Set-2 RhoAV14-expressing rat eyes were
found to be 14.2  0.6 mm Hg (means  SEM; nZ 12) and
signiﬁcantly higher (P < 0.01) than in the saline-injected
(11.8  0.73 mm Hg) and GFP-expressing (11.3  0.9 mm
Hg) rats. Increased IOP in the RhoAV14-expressing eyes was
sustained until the end of the study (155 days after injection).
The mean percentage  SEM increase in IOP in the
RhoAV14-expressing eyes was 21.7%  0.46 % (Set 1) and
21.3% 2.18% (Set 2) compared with the saline-injected and
GFP-expressing control eyes (Supplemental Table S2). The
noninjected contralateral eyes did not show any signiﬁcant
difference in IOP among the three groups in both Set-1 and
Set-2 rats (data not shown). In the Set-1 rats, IOPs were also
measured at night on days 116 and 136 after injections. As is
well known,56 IOP values were higher at night in all three
groups (Figure 2). Moreover, the nightly values of IOP in the
RhoAV14-expressing rat eyes were signiﬁcantly higher (by
33.4% 0.36%; nZ 8) than in the respective saline and GFP
control rat eyes (Supplemental Table S2).
RhoAV14 Expression in the Trabecular AH Outﬂow
Pathway of Rats Induces Contractile Response
At the end of the IOP evaluation (155 days) studies
described in the previous section, rats were sacriﬁced, and501
Figure 2 The expression of RhoAV14 in the iridocorneal angle of live
rats induces elevated IOP. Two sets of Sprague-Dawley rats were injected
intracamerally with 10 mL of saline solution (group I) or 1  107 TU/mL
of either GFP- (group II) or RhoAV14 (group III)-expressing vector
particles (Set-1 and Set-2). The injections were administered to the
right eye, with the contralateral left eye serving as the untreated
control. The day of injection was considered as day 1. IOPs were
measured a few days before (<7 days) the intracameral injections to
record basal values and were continued after injections for up to day
155, with IOP measurements being performed once every 3 to 4 weeks.
Day-time IOPs were measured (Set-1 and Set-2) between 10 AM and 1 PM,
with night-time IOPs (Set-1) being measured between 10 PM and 1 AM.
IOPs were compared at the indicated time points between the saline-
treated and the GFP- and RhoAV14-expressing groups. Analysis of
variance was performed to test IOP changes between saline-, GFP-, and
RhoAV14-injected groups. If the test proved signiﬁcant, independent
groups were assessed for signiﬁcance by using the nonparametric Wil-
coxon rank sum test. A and B: Histograms show the day-time IOP values
in the right eye (injected) of rats from Set-1 and Set-2, respectively,
during the pre- and postinjection periods. The RhoAV14-expressing eyes
display a signiﬁcant increase in IOP compared with controls (saline-
injected or GFP-expressing groups) at days 68 and 94 after injection in
the Set-1 and Set-2 rats, respectively. The triangle on the x axis in-
dicates the day of intracameral injections. C: Histograms of the night-
time IOP values in the right eye of injected rats at the indicated
postinjection periods. Values are expressed as means  SEM. n Z 8 per
Set-1 group; n Z 12 per Set-2 group. *P < 0.05. GFP, green ﬂuorescent
protein; IOP, intraocular pressure; RhoAV14, constitutively active RhoA
GTPase; TU, transduction unit.
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502the enucleated eyes from all three groups (RhoAV14/GFP,
GFP, and saline) were processed to analyze the distribution
proﬁle of GFP, which served as a reporter gene that
conﬁrmed expression of the candidate recombinant protein
(RhoAV14 GTPase) in lentiviral vector-injected rat eyes.
Sagittal plane thin cryosections of rat eye anterior segments
through the iridocorneal angle mounted onto glass slides
were directly visualized under a ﬂuorescence microscope to
assess GFP expression and distribution in the AH outﬂow
pathway. Analysis of rat eyes injected (intracamerally) with
RhoAV14/GFP- or GFP-expressing viral vectors conﬁrmed
the expression of GFP in the iridocorneal angle, including
ciliary body and the trabecular AH outﬂow pathway (TM and
SC) (Figure 3A). As expected, no GFP was found in the eyes
of saline-injected rats. A minimum of four individual speci-
mens from each group were examined to conﬁrm expression
of recombinant proteins in the AH outﬂow pathway on the
basis of GFP expression, and all specimens from both the
RhoAV14/GFP and GFP groups were conﬁrmed to express
GFP. Expression of GFP is much stronger in the iridocorneal
angle than in other ocular tissues (eg, cornea) (Figure 3A),
and the lens tissue did not exhibit detectable GFP expression
(data not shown). In addition, lentiviral vector-based
expression of either RhoAV14 or GFP in the iridocorneal
angle of rat eye did not cause any noticeable effect on the
anterior chamber angle opening. Light microscope-based
histologic examination of the eye specimens from all three
groups showed an open anterior chamber angle morphology,
conﬁrming that the changes noted in IOP of RhoAV14-
expressing rats are not related to structural integrity of the
eye anterior chamber angle (Figure 3B).
To conﬁrm the functionality of the recombinant RhoAV14
expressed in vector-injected rat eyes, we examined changes
in F-actin distribution (Figure 3C) and pMLC (Figure 3D) in
tissues of the AH drainage pathway. These experiments were
performed by confocal microscopy-based monitoring of
rhodamineephalloidin-based (F-actin) ﬂuorescence and
pMLC immunoﬂuorescence, respectively, using tissue cry-
osections derived from all three groups (RhoAV14/GFP,
GFP, and saline). The ﬂuorescence staining intensity for
F-actin was relatively intense in the TM and SC of
RhoAV14-expressing specimens compared with GFP-
expressing (Figure 3C) and saline (data not shown) con-
trols. F-actin staining associated with the ciliary muscle and
iris in RhoAV14-expressing specimens was not different
from that found in the GFP (Figure 3C) and saline (data not
shown) controls. Consistent with the increase in F-actin
staining intensity, pMLC immunoﬂuorescence was also
found to be much higher in the AH outﬂow pathway region,
especially in the TM and SC tissues in RhoAV14-expressing
specimens, than in the GFP (Figure 3D) and saline (data not
shown) controls. Appropriate negative controls for the
nonspeciﬁc tissue and secondary antibody ﬂuorescence were
included in these comparisons (data not shown).
Before proceeding further, we attempted to determine
whether inﬂammation or immunologic reactions contributedajp.amjpathol.org - The American Journal of Pathology
RhoA-Induced Ocular Hypertension in Ratsto the viral vector-mediated effects within the anterior
chamber angle of the eye. We examined the expression and
distribution proﬁles of markers for macrophage (F4/80) and
monocytes (Iba1)57 by immunoﬂuorescence staining of tis-
sue cryosections. These analyses did not reveal any positive
staining for either of the inﬂammatory markers in the iri-
docorneal angle, indicating that lentiviral vector injections
in the eye anterior chamber did not trigger inﬂammation or
immunologic reaction (data not shown).
RhoAV14 Expression in the AH Outﬂow Pathway of
Rats Induces Fibrotic Changes
To determine whether elevated IOP in the RhoAV14-
expressing rats is associated with the structural alterations
in the AH outﬂow pathway, we examined the histology andThe American Journal of Pathology - ajp.amjpathol.orgultrastructure of the AH outﬂow pathway by light micro-
scopy and TEM. Analysis of semithin sections by light mi-
croscopy did not show structural difference in the opening of
the eye anterior chamber angle in RhoAV14-expressing rats
(Figure 4) compared with that in GFP-expressing specimens
(Figure 4). Because we did not ﬁnd differences in IOP or
anterior chamber angle histology between the GFP-
expressing control rats and saline-injected rats, further
analysis of ultrastructural changes in the trabecular AH
outﬂow pathway by TEM focused only on comparison of
changes between RhoAV14/GFP-expressing and GFP-
expressing (control) specimens. TEM of the eye anterior
chamber angle specimens revealed noticeable compaction of
the TM and JCT in >60% of the RhoAV14/GFP-expressing
eyes compared with the GFP-expressing eyes (Figure 4).
Unlike in GFP-expressing control specimens, in which the
TM beams appear to be loose with noticeable spaces be-
tween the beams, the TM beams/JCT area appeared compact
and dense in the RhoAV14-expressing specimens (Figure 4).
This ﬁbrotic/ultrastructurally dense-looking TM in RhoAV14
eyes was associated with optically dense extracellular ma-
terial relative to the GFP controls in which there seemed to
be more optically empty space between the beams
(Figure 4B). Importantly, in support of this conclusion,
because it relates to possible changes in the ECM within the
trabecular AH outﬂow pathway of RhoAV14-expressing
specimens, we performed immunogold labeling for
collagen-1A. The results indicated that collagen-1A was
distributed mostly within the TM and JCT regions, with
relatively higher/denser accumulation of gold particle
deposition observed in the RhoAV14-expressing specimens
compared with the GFP-expressing controls (Figure 4C).
The images are representative of a total of four to six in-
dependent specimens analyzed in the study.Figure 3 Expression of GFP and RhoAV14/GFP in the iridocorneal angle
of live rats and contractile changes in the AH outﬂow pathway. A: Anterior
chamber tissue cryosections derived from rat eyes injected intracamerally
with GFP- or RhoAV14/GFP-expressing viral vector particles show GFP-
speciﬁc green ﬂuorescence in the conventional AH pathway, conﬁrming
the expression of recombinant proteins with lentivirus-based gene delivery
approach. GFP expression was distributed in the AH outﬂow pathway tract
mainly in the TM and around the walls of SC. GFP expression was also seen
in the regions around the CB. The saline-injected rat eyes, as expected, did
not exhibit GFP-speciﬁc green ﬂuorescence. B: Light microscope-based
histologic examination of the rat eyes injected with viral particles that
express either RhoAV14/GFP or GFP alone or injected with saline alone show
indistinguishable and normal morphology of open AH drainage angle in all
three groups, conﬁrming no notable adverse inﬂuence of vector on the
opening of AH drainage angle. C and D: The AH outﬂow pathway tissues
(cryosections), including TM and SC, show increased levels of F-actin and
pMLC on the basis of rhodamine-phalloidin ﬂuorescence staining and anti-
pMLC immunoﬂuorescence staining, respectively, in the RhoAV14-
expressing rats (arrows) compared with the GFP-expressing control rats.
Lower panels show magniﬁed area of the AH outﬂow pathway in which the
changes in F-actin and pMLC are easily evident. Scale bars: 50 mm (AeD).
AH, aqueous humor; CB, ciliary body; GFP, green ﬂuorescent protein; pMLC,
phosphorylated myosin light chain; RhoAV14, constitutively active RhoA
GTPase; SC, Schlemm canal, TM, trabecular meshwork.
503
Figure 4 Expression of RhoAV14 in the iridocorneal angle of live rats
induces ultrastructural and ﬁbrotic alterations in the AH outﬂow pathway.
A: Light microscopy-based histologic analysis of the eye anterior chamber
angle in RhoAV14/GFP-expressing rats compared with GFP-expressing
controls shows no gross structural differences in the conventional
outﬂow pathway. B: The TEM-based histologic analysis of the AH outﬂow
pathway of RhoAV14-expressing rat eyes reveals compaction and ﬁbrotic
appearance (double-headed arrows) of both TM and JCT compared with
the GFP-expressing control eyes. C: Immunogold labeling of collagen-1A in
the AH outﬂow pathway tissues of RhoAV14-expressing eyes shows rela-
tively intense labeling in the TM and JCT region (asterisks) compared with
the GFP-expressing control specimens. Tissue compaction and ﬁbrotic
appearance is indicated by double-headed arrow. n Z 4 independent
specimens. Scale bars: 50 mm (A); 5 mm (B); 2 mm (C, left panels); 1 mm
(C, right panels). AH, aqueous humor; EM, electron microscopy; GFP, green
ﬂuorescent protein; JCT, juxtacanalicular tissue; RhoAV14, constitutively
active RhoA GTPase; SC, Schlemm canal; TEM, transmission electron mi-
croscopy; TM, trabecular meshwork.
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Pathway of Rats Induces Accumulation of Collagen-1A,
Total Collagen, and a-SMA
On the basis of the histologic observations described in the
previous section which suggest a possible ﬁbrotic response in
the RhoAV14-expressing rat AH outﬂow pathway, we
evaluated for changes in the levels of collagen-1A, total
collagen, and a-SMA by immunohistochemical analysis and
Sirius Red staining with the use of parafﬁn-embedded tissue
sections from RhoAV14-expressing (nZ 4 from Set 2) and
GFP-expressing (nZ 4 from Set-2) specimens. The anterior-504chamber angle of RhoAV14-expressing eyes exhibited a
relatively strong positive immunostaining for a-SMA
(Figure 5A) and collagen-1A (Figure 5B) and deposition of
total collagen as detected by Sirius Red staining (Figure 5C)
compared with eyes expressing GFP alone (Figure 5, AeC).
The ciliary body, which stained positive for a-SMA,
collagen-1A, and total collagen in the GFP- and the
RhoAV14-expressing specimens, exhibited higher staining
intensity for each of the three proteins in the RhoAV14-
expressing specimens. In addition to the visual comparison
of staining intensity shown in Figure 5, we used a grading
system comprised of masked result review by two indepen-
dent reviewers (nZ 4 samples from Set-2, with each sample
immunostained and analyzed in triplicate). Nonparametric
comparison of the calculated scores for staining intensity
conﬁrmed that specimens from RhoAV14-expressing eyes
exhibited higher staining intensity than the GFP-expressing
control eye specimens for a-SMA (Figure 5D). However,
this difference was found to be statistically signiﬁcant only in
the SC region (42% increase) of RhoAV14-expressing
specimens compared with the corresponding region from
GFP-expressing controls (Figure 5D). Although the staining
intensity of a-SMA in the TM/JCT combined region from
RhoAV14-expressing eyes was increased by 22% compared
with the corresponding region in GFP-expressing specimens,
this difference was not signiﬁcant (Figure 5D). However, the
immunostaining intensity of collagen-1A and Sirius Red
staining of total collagen showed a signiﬁcant increase by
approximately 50% in the TM and SC regions in RhoAV14-
expressing specimens (P < 0.03 and P < 0.02, respectively;
n Z 4) compared with the GFP-expressing specimens
(Figure 5D and Supplemental Table S3).
Y27632 Lowers IOP by Suppressing the Fibrogenic
Response in the TM of RhoAV14-Expressing Rats
To determine whether the effects of RhoAV14 on IOP are
mediated via Rho kinase, we tested the topical effects of
Y27632, a well-characterized small molecular weight Rho
kinase inhibitor on IOP in the RhoAV14-expressing rats.39
For this experiment (Set-3), intracameral injections of
either saline (nZ 6), vector particles expressing GFP (nZ
7), or RhoAV14/GFP (n Z 7) were administered to the
anterior chamber of the right eye in adult live rats, with the
untreated contralateral left eye serving as untreated control.
IOP was subsequently monitored for nearly 22 weeks as
described earlier (Figure 2). After this, Y27632 was applied
topically (4 mL of 10 mmol/L in PBS; twice with 30-second
delay) once per day to the right eye, whereas the contra-
lateral (left) eye received PBS (4 mL, twice) for a total of 15
days. IOPs were recorded under mild anesthesia, between 1
and 1.5 hours after administration of Rho kinase inhibitor,
on days 1, 3, 8, 11, and 15, as described earlier. Consistent
with the data obtained from rats from Set-1 and Set-2, the
RhoAV14-expressing rats in Set-3 exhibited signiﬁcant
elevation (P < 0.001; n Z 7) in IOP, starting from day 54ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Evidence for RhoAV14-induced ﬁbrogenic activity in the AH outﬂow pathway of live rats. AeC: Representative images of immunohistochemical
localization of a-SMA and collagen-1A and Sirius Red stain of total collagen, respectively, in the AH outﬂow pathway of RhoAV14-expressing and GFP-
expressing rat specimens (parafﬁn-embedded). On the basis of relative intensity of staining pattern within the AH outﬂow pathway, the RhoAV14-
expressing specimens show increased levels of a-SMA, collagen-1A, and total collagen in the TM, JCT, and SC compared with the GFP-expressing eyes. D:
Quantiﬁcation of the staining intensity on the basis of grading done by two individuals in a masked manner shows an increase of a-SMA staining intensity in
both TM (21.7%) and SC (42%); however, it was found to be signiﬁcant only in the SC of RhoAV14-expressing specimens compared with the GFP controls
(P < 0.03). Collagen-1A shows signiﬁcantly increased staining intensity in both TM (P < 0.03) and SC (P < 0.03) of RhoAV14-expressing specimens compared
with the GFP-expressing controls. Likewise, the total collagen staining based on Sirius Red stain shows a signiﬁcant increase in the TM (P < 0.02) and SC
(P < 0.03) of RhoAV14-expressing specimens compared with the GFP-expressing controls. The box and whisker plots represent median and the interquartile
range in the distribution. nZ 4 RhoAV14-expressing specimens (D). *P < 0.05. Scale bars: 20 mm (AeC). AH, aqueous humor; GFP, green ﬂuorescent protein;
JCT, juxtacanalicular tissue; RhoAV14, constitutively active RhoA GTPase; SC, Schlemm canal; a-SMA, a-smooth muscle actin; TM, trabecular meshwork.
RhoA-Induced Ocular Hypertension in Ratscompared with the saline (nZ 6; data not shown) and GFP
(nZ 7) expressing rats (Figure 6). This trend was sustained
until day 155 consistent with the observations from Set-1
and Set-2. The percentage increase in IOP in the
RhoAV14-expressing rats was approximately 23.4% at day
155 relative to the GFP and saline control rats. After treat-
ment with Y27632, no difference was detected in IOPThe American Journal of Pathology - ajp.amjpathol.orgbetween the RhoAV14-expressing and GFP-expressing and
saline-treated (data not shown) control rats. Topical
administration of Y27632 was found to cause a signiﬁcant
(20%) decrease in the IOP in RhoAV14-expressing rat eyes
(Figure 6 and Supplemental Table S4). GFP-expressing
control rat eyes exhibited a slight (4%) but insigniﬁcant
decrease in IOP in response to topically administered505
Figure 7 Rho kinase inhibitor ameliorates the RhoAV14-induced
ﬁbrotic activity in the AH outﬂow pathway of rats. A: Light microscopy-
based histologic analysis of iridocorneal angle of RhoAV14-expressing rat
specimens and Rho kinase inhibitor-treated RhoAV14-expressing rat spec-
imens show comparable and normal integrity. B: TEM-based histologic
analyses of the RhoAV14-expressing specimens show a compact and
ﬁbrotic-looking AH outﬂow pathway. However, on treatment with Rho ki-
nase inhibitor (topical), the AH outﬂow pathway of RhoAV14-expressing rat
specimens appear normal with wide spaces in the TM (asterisk). C: Rho
AV14-expressing eyes show an intense labeling of collagen-1A on the basis
of immunogold labeling in the TM and JCT region, on treatment with Rho
kinase inhibitor a signiﬁcant reduction in collagen-1A labeling is noted in
the AH outﬂow pathway. n Z 4 independent samples. Scale bars: 50 mm
(A); 1 mm (B); 2 mm (C, left panels); 1 mm (C, right panels). AH, aqueous
humor; EM, electron microscopy; GFP, green ﬂuorescent protein; JCT, jux-
tacanalicular tissue; RhoAV14, constitutively active RhoA GTPase; SC,
Schlemm canal; TEM, transmission electron microscopy; TM, trabecular
meshwork; Y27632, Rho kinase inhibitor [(R)-(þ)-trans-N-(4-Pyridyl)-4-
(1-aminoethyl)-cyclohexanecarboxamide dihydrochloride].
Figure 6 Rho kinase inhibitor decreases IOP induced by RhoAV14 in
live rats. Sprague-Dawley rats (Set-3) injected intracamerally with GFP-
expressing viral vector or RhoAV14/GFP-expressing viral vector (1  107
TU/mL in 10 mL) show a signiﬁcant increase in day-time IOP in the
RhoAV14-expressing rats, starting from day 54 after injection, with the
trend continuing until day 155. After this period (155 days), the right eyes
from rats injected with virus were treated with Rho kinase inhibitor (10
mmol/L Y27632; two 4-mL drops; once daily for 15 days). Eyes from
RhoAV14-expressing rats treated with the Rho kinase inhibitor exhibit a
signiﬁcant decrease in IOP compared with IOP in the same rats before the
treatment with Y27632. Rho kinase inhibitor also decreases IOP in the GFP-
expressing controls compared with IOP of the same respective groups
before the Rho kinase inhibitor; however, the difference is not signiﬁcant
between these two groups. Values are expressed as means  SEM. n Z 7
rats in each group. *P < 0.05. GFP, green ﬂuorescent protein; IOP,
intraocular pressure; RhoAV14, constitutively active RhoA GTPase; TU,
transduction unit; Y27632, Rho kinase inhibitor [(R)-(þ)-trans-N-(4-
Pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide dihydrochloride].
Pattabiraman et alY27632. The contralateral eyes treated with PBS showed a
slight decrease in IOP, but this decrease not found to be
signiﬁcant compared with basal values in either RhoAV14
or GFP-expressing or in saline-treated rat eyes (data not
shown). We excluded IOP values from analysis acquired on
day 1 after treatment with Rho kinase inhibitor (Figure 6)
because of the erratic nature of the Tonopen recordings.
On completion of the IOP studies, ultrastructural and
immunohistochemical analyses were performed to evaluate
the effects of Y27632 on the ﬁbrogenic response evoked by
RhoAV14 in the trabecular AH outﬂow pathway. We used
the GFP- and RhoAV14-expressing specimens from Set-2 to
compare with the Y27632-treated specimens (Set-3; nZ 3).
Examination of the histologic structure of the anterior
chamber angle of GFP- and RhoAV14-expressing speci-
mens in the presence and absence of Rho kinase inhibitor did
not reveal any noticeable differences (Figure 7A). TEM
analyses of specimens from RhoAV14-expressing eyes
treated with topical Y27632 (Figure 7B) revealed a marked
absence of the extracellular material deposition noted in the
TM and JCT regions of untreated RhoAV14-expressing
eyes. This effect of Y27632 was also evidenced by the
large and wide optically empty spaces in the TM and JCT
regions (Figure 7B) of RhoAV14-expressing specimens
treated with Y27632, as opposed to RhoAV14-expressing
eyes exhibited ﬁbrotic and histologically compacted506changes (Figure 7B). Immunologic electron microscopy for
collagen-1A showed decreased collagen-1Aedense parti-
cles in the AH outﬂow pathway of RhoAV14-expressing
eyes treated with Y27632 (Figure 7C) compared with
untreated specimens (Figure 7C). Saline-treated and GFP-
expressing specimens that received Y27632 drops exhibi-
ted comparable levels of collagenous material in the TM and
JCT regions of the outﬂow pathway with no clear differences
relative to those noted between the GFP- and RhoAV14-
expressing specimens (Set-2; data not shown).
Immunohistochemical analyses of a-SMA and collagen-
1A and Sirius Red stain analysis for total collagen were alsoajp.amjpathol.org - The American Journal of Pathology
RhoA-Induced Ocular Hypertension in Ratsperformed to compare the effects of the Rho kinase inhibitor
on RhoAV14-induced changes in the AH outﬂow pathway
(Figure 8). Immunostained and Sirius Red-stained speci-
mens were graded in a masked manner, and the average
values of grading scores were evaluated for statistically
signiﬁcant differences. RhoAV14-expressing rat eyes
treated with Y27632 exhibited a signiﬁcant decrease in
immunostaining for a-SMA (P < 0.03; nZ 3) (Figure 8, A
and D) and collagen-1A (P < 0.03; nZ 3) (Figure 8, B and
D) and in Sirius Red staining for total collagen (P < 0.03;
nZ 3) (Figure 8, C and D) in the TM/JCT areas, relative to
untreated RhoAV14-expressing rat eyes. Collagen-1A
expression (P < 0.02; n Z 3) and total collagen distribu-
tion (P < 0.02; n Z 3) were also decreased signiﬁcantly
around the endothelial walls of SC (Figure 8, BeD),
whereas a-SMA expression was unaltered (P < 0.08; n ZFigure 8 Rho kinase inhibitor suppresses the RhoAV14-induced expression of
AeC: Representative images of immunohistochemical localization of a-SMA and c
outﬂow pathway of RhoAV14-expressing eyes treated or untreated with Y27632
marked decrease in the staining intensity of a-SMA, collagen-1A, and total colla
untreated RhoAV14-expressing specimens. D: Histograms depict changes in the
outﬂow pathway of RhoAV14-expressing rat specimens treated or untreated wit
dividuals. Treatment with Y27632 decreases the staining intensity of a-SMA, collag
untreated RhoAV14-expressing specimens. Similarly, the staining of collagen-1A
pathway of RhoAV14-expressing specimens treated with Y27632 compared with the
median and the interquartile range in the distribution. nZ 4. *P < 0.05. Scale ba
GTPase; SC, Schlemm canal; a-SMA, a-smooth muscle actin; TM, trabecular m
aminoethyl)-cyclohexanecarboxamide dihydrochloride].
The American Journal of Pathology - ajp.amjpathol.org3) in the Y27632-treated specimens compared with the
RhoA-expressing specimens (Figure 8A). The percentage
change in score calculated for Rho kinase inhibitor-treated
RhoAV14-expressing specimens were all negative, indi-
cating a decrease in the staining intensity relative to the
corresponding untreated, RhoAV14-expressing eyes
(Supplemental Table S5).
Human Glaucoma Eye Specimens Exhibit Increased
Accumulation of Collagen-1A and Collagen in the
Trabecular AH Outﬂow Pathway
To determine the relevance of the ﬁndings from the rat model
for ECM-associated changes in the trabecular AH outﬂow
pathway of human glaucoma and age-matched control eyes,
we evaluated the distribution and accumulation of collagen-1Aa-SMA, collagen-1A, and total collagen in the AH outﬂow pathway of rats.
ollagen-1A and of total collagen on the basis of Sirius Red stain in the AH
, respectively. Daily, topical application of Y27632 for 15 days leads to a
gen both in the TM and SC of the RhoAV14-expressing eyes compared with
intensity of staining of a-SMA, collagen-1A, and total collagen in the AH
h Y27632. Staining intensity was graded in a masked manner by two in-
en-1A, and total collagen in the TM compared with the staining recorded in
and total collagen in the SC is signiﬁcantly decreased in the AH outﬂow
untreated RhoAV14-expressing specimens. Box and whisker plots represent
rs: 20 mm (AeC). AH, aqueous humor; RhoAV14, constitutively active RhoA
eshwork; Y27632, Rho kinase inhibitor [(R)-(þ)-trans-N-(4-Pyridyl)-4-(1-
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Figure 9 Increased collagen-1A accumulation in the AH outﬂow
pathway of human glaucoma specimens. A: The images depict the distri-
bution pattern of collagen-1A in the AH outﬂow pathway of age-matched
nonglaucoma control subjects and glaucoma subjects. The glaucoma
specimens show intense immunostaining of collagen-1A in both the CS-TM
and US-TM, which is distributed at moderate levels throughout the JCT and
SC. B: Grading of staining intensity of collagen-1A in the AH outﬂow
pathway by three individuals in a masked manner reveals a signiﬁcant
increase in both the CS-TM and US-TM (P < 0.01 and 0.003, respectively) in
the glaucoma specimens compared with the age-matched nonglaucoma
specimens. The difference in staining intensity of collagen-1A in the JCT
and SC regions of glaucoma and control specimens is insigniﬁcant. nZ 10
(B). *P < 0.05. Scale bars: 100 mm (A). AC, anterior chamber; AH, aqueous
humor; CB, ciliary body; CS_TM, corneoscleral trabecular meshwork; JCT,
juxtacanalicular tissue; SC, Schlemm canal; US_TM, uveoscleral trabecular
meshwork.
Figure 10 Increased total collagen staining in the AH outﬂow pathway
of human glaucoma specimens. A: Images show the distribution proﬁle of
total collagen in the AH outﬂow pathway of age-matched nonglaucoma and
glaucoma specimens on the basis of Sirius Red staining. Compared with age-
matched control specimens, the glaucoma human specimens show intense
staining for total collagen in the areas of CS-TM, US-TM, JCT, and SC. B:
Grading values derived on the basis of the intensity of Sirius Red stain by
three individuals in a masked manner reveals a signiﬁcant increase in total
collagen in the regions of CS-TM, US-TM, JCT, and SC of glaucoma specimens
compared with the age-matched controls. nZ 10. *P< 0.05; Scale bars: 100
mm (A). AC, anterior chamber; AH, aqueous humor; CB, ciliary body; CS_TM,
corneoscleral trabecular meshwork; JCT, juxtacanalicular tissue; SC, Schlemm
canal; US_TM, uveoscleral trabecular meshwork.
Pattabiraman et aland total collagen by immunostaining analysis and Sirius
Red staining, respectively, of parafﬁn-embedded autopsy
eyes from glaucoma (nZ 10) and age-matched nonglaucoma
(n Z 10) patients. The demography details, including age,
sex, race, and medication of these patients, are described in
Supplemental Table S1 and conﬁrm there were no signiﬁcant
differences in any of these factors between the glaucoma and
nonglaucoma patients used in this study. The relative staining
intensity of collagen-1A and total collagen was graded by
three individuals in a masked fashion, and average scores were
compared statistically. The nonglaucoma eyes displayed
detectable positive staining for both collagen-1A (Figure 9A)
and total collagen (Figure 10A) in the TM and JCT regions.508Relatively weak staining was noted in the SC region compared
with the TM and JCT regions for both proteins, particularly for
collagen-1A (Figure 9, A and B). The relative staining in-
tensity scores for collagen-1A and total collagen derived from
the different regions of AH outﬂow pathway are shown in
Figures 9B and 10B, respectively. The glaucoma eye speci-
mens showed a signiﬁcant increase in collagen-1A staining in
the TM, including both the CS-TM (P < 0.01; nZ 10) and
US-TM (P < 0.003; nZ 10) (Figure 9A) regions compared
with the nonglaucomatous specimens. Interestingly, the
staining pattern of collagen-1A in the JCT and SC regions of
glaucoma specimens did not show much difference compared
with the nonglaucoma specimens (Figure 9, A and B). The
total collagen distribution evaluated by Sirius Red staining
presented as a strong signal in the AH outﬂow pathway of bothajp.amjpathol.org - The American Journal of Pathology
RhoA-Induced Ocular Hypertension in Ratsglaucoma and nonglaucoma specimens (Figure 10A). How-
ever, the relative staining intensity of total collagen in the
glaucomatous eyes was found to be signiﬁcantly higher in the
TM, including CS-TM (P < 0.01; n Z 10), US-TM
(P < 0.003; n Z 10), JCT (P < 0.03; n Z 10), and SC
(P < 0.008; nZ 10) (Figure 10, A and B) regions, compared
with the nonglaucomatous control specimens.Discussion
Our objective was to determine whether dysregulated Rho
GTPase signaling in the AH outﬂow pathway affects ho-
meostasis of IOP, and if in fact it does inﬂuence IOP, to
understand the molecular basis for such alterations. To
address this objective on a mechanistic level with the use of
an experimental animal model, we investigated the effects
of expressing a constitutively active RhoA GTPase mutant
(RhoAV14) on IOP, using a lentiviral vector to target
RhoAV14 expression to the AH outﬂow pathway of live
rats. Here, we demonstrated not only that sustained activa-
tion of Rho GTPase signaling in the conventional AH
outﬂow pathway induces OHT in live rats but importantly
that the elevated IOP appears to be associated with
augmented ﬁbrogenic activity in the cells of the AH outﬂow
pathway in a Rho kinase-dependent manner. Moreover, we
record evidence for an increased accumulation of collagen-
1A and total collagen in the trabecular AH outﬂow pathway
of human glaucoma specimens. These observations collec-
tively infer that increased ﬁbrogenic activity of the cells of
the conventional AH outﬂow pathway induced by the
dysregulated cellular mechanisms, especially the Rho/Rho
kinase signaling pathway which controls the contractile and
biomechanical properties of cells and tissues, impairs AH
outﬂow through the TM, resulting in OHT. Signiﬁcantly,
inhibition of Rho kinase activity ameliorates the ﬁbrotic
responses of TM and lowers IOP, further supporting the
promising therapeutic potential of Rho kinase inhibitors in
lowering IOP in glaucoma patients.28,46,51
OHT, a primary risk factor for POAG is well recognized
to be the result of increased resistance to AH outﬂow
through the conventional pathway.7,8 Among various
possible mechanisms involved in increased resistance to AH
outﬂow, it is becoming increasingly evident that the accu-
mulation of ECM and associated matrix stiffness, altered
contractile and material properties of the TM, is considered
to be some of the signiﬁcant factors that contribute to
elevated IOP.8,16,18,23,28 Most signiﬁcantly, POAG patients
are known to have elevated levels of TGF-b2, CTGF,
endothelin-1, and autotaxin activity in the AH.24e27 More-
over, these different factors were found to inﬂuence the
contractile properties of TM tissue, ECM synthesis, and
actin cytoskeletal reorganization by activating Rho GTPase/
Rho kinase signaling and other signaling pathways.20e23,30
However, in a broader sense the molecular mechanisms
involved in increased resistance to AH outﬂow are not wellThe American Journal of Pathology - ajp.amjpathol.orgunderstood.8,18 In addition, despite overwhelming interest
from the pharmaceutical industry to explore the therapeutic
use of Rho kinase inhibitors in lowering IOP in glau-
coma,46,51 we still do not have a complete understanding of
the cellular basis by which Rho kinase inhibitors increase
AH outﬂow through the TM and how these inhibitors may
reduce resistance to AH outﬂow.
RhoA and IOP
Toward a better understanding of the signiﬁcance of Rho/
Rho kinase signaling in regulating the resistance to AH
outﬂow and on the basis of our recent observations in
cultured TM cells, in which we gained mechanistic evi-
dence for the role of Rho GTPase signaling in ECM syn-
thesis and organization and the expression of a-SMA,21,30
here, we investigated the in vivo effects of a constitutively
active form of Rho GTPase on IOP in a rat model. For a
mechanistic understanding and to induce sustained Rho
GTPase activity, we expressed RhoAV14 under the control
of a cytomegalovirus promoter in the AH outﬂow pathway
of rat eye, using a lentivirus vector-based gene delivery and
intracameral administration of viral vector particles.
Expression of RhoAV14, which is conﬁrmed by detecting
GFP tracer protein ﬂuorescence in the AH outﬂow
pathway, increased IOP signiﬁcantly and consistently in
three independent sets of rats in the absence of detectable
inﬂammation. As expected, RhoAV14 expression is not
restricted to the conventional AH outﬂow pathway and was
detected in the ciliary muscle and iris as well. Although the
lentivirus-based gene expression approach maintained a
sustained expression of RhoAV14 in the AH outﬂow
pathway for >15 weeks and IOP continued to be elevated
signiﬁcantly compared with the GFP controls, IOP did not
increase progressively after the initial signiﬁcant increase
noted by 7 to 9 weeks after injections. Moreover, with this
gene delivery approach, there was only 20% to 30%
elevation in IOP during day and night compared with the
GFP controls. The possible reason for this modest elevation
in IOP with RhoAV14 expression could be relevant to the
inherent inefﬁcient approach available to induce the re-
combinant gene expression in the conventional pathway
and insufﬁcient viral vector concentration used in this
study. Ideally, 1  108 TU/mL of viral vector particles
would have been appropriate, but we could not generate
this high titer and used a titer of 1  107 TU/mL instead.
However, although IOP was elevated moderately but
signiﬁcantly in the RhoAV14-expressing rats, it was sus-
tained until the rats were sacriﬁced at 22 weeks after in-
jection. As is known, the use of lentiviral vector is
associated with a considerable delay (ranging between 7
and 9 weeks) relative to adenoviral gene delivery,53 in the
context of detecting the initial signiﬁcant differences in
IOP in RhoAV14-expressing rats. In addition, it is neces-
sary to note here that we recorded IOP only once every 3
to 4 weeks. Therefore, there could be a 1- to 2-week509
Pattabiraman et aldiscrepancy in our estimation of the exact time of onset of
elevated IOP in the RhoAV14-expressing rats.
RhoA and Fibrogenic Activity in the AH Outﬂow
Pathway
Although an initial glimpse into the histologic integrity of the
AH outﬂow pathway in the RhoAV14-expressing rats by light
microscopy showed no abnormality in the opening of the
anterior chamber angle, we noted the appearance of a relatively
more compact and ﬁrm AH outﬂow pathway in a high number
(>60%) of these rats by TEM, compared with the GFP-
expressing controls (approximately 15%). The TM beams in
particular were found to display a ﬁbrotic or stiffened
morphology in the RhoAV14 AH pathway relative to the GFP
controls. Importantly, this histologic phenotype in the
RhoAV14-expressing specimens was associated with
increased accumulation of collagen-1A in the conventional
outﬂow pathway as detected by immunologic electron micro-
scopy. After these observations and the use of immunohisto-
chemical analysis of parafﬁn-embedded tissue specimens, we
recorded signiﬁcantly elevated levels of a-SMA, collagen-1A,
and total collagen in the AH outﬂow pathway of RhoAV14-
expressing rats compared with the GFP controls. These ob-
servations in the AH outﬂow pathway are not only consistent
with the changes that we reported in the RhoAV14-expressing
cultured human TM cells but also conﬁrm that elevated IOP
associates closely with increased levels of a-SMA, collagen-
1A, and total collagen in the AH outﬂow pathway.21,30
Moreover, these changes most likely are involved in altered
material properties (stiffer or ﬁbrotic appearance) of AH
outﬂow pathway noted in the RhoAV14-expressing speci-
mens. It is highly likely that the increase in levels of a-SMA,
collagen-1A, and total collagen observed in the AH outﬂow
pathway of RhoAV14-expressing rat specimens is induced by
the actin/ serum response factor/ myocardin-related transcrip-
tion factor transcriptional axis in response to sustained activa-
tion of Rho GTPase activity as we have found in cultured TM
cells.21,30 This possibility has not been conﬁrmed in the present
study, however, because of limitations with availability of TM
tissue from rats. Similarly, conﬁrmation of whether the
increased levels of a-SMA, collagen-1A, and total collagen in
the AH outﬂow pathway of RhoAV14-expressing rat speci-
mens derive from myoﬁbroblast activation and endothelial-to-
mesenchymal transition of TM cells will require additional
studies.30 However, increased RhoA activity was demonstrated
to induce ﬁbrotic response in various tissues31,58e63 and to play
a signiﬁcant role in TGF-be and CTGF-induced epitheial-
mesenchymal transition/endothelial-to-mesenchymal transition
and ECM synthesis in different cell types.23,30,31,59 Moreover,
our previous study has reported that Rho GTPase activation in
TM cells induces expression of TGF-b2 and CTGF, which are
recognized proﬁbrogenic factors.29 Whether the optic nerve
head in RhoAV14-expressing rats shows ﬁbrogenic changes
similar to those observed in the AH outﬂow pathway was not
determined in this study.510Rho Kinase Inhibitor and Ocular Hypotensive Activity
Taken together, it is plausible that increased IOP in the
RhoAV14-expressing rats could be associated with increased
resistance to AH outﬂow through the conventional pathway
because of alterations in collagen synthesis and deposition
and the resulting effect on material properties of AH pathway
tissues such as the TM and SC. Therefore, it is possible that
the noted delay in onset of signiﬁcant elevation in IOP in the
RhoAV14-expressing rats observed in this study could also
be related to a gradual progression of ﬁbrosis or ﬁbrogenic
activity in the conventional AH pathway induced by Rho
GTPase activation. Because we did not measure AH outﬂow
facility in this study, we cannot rule out possible involvement
of the nonconventional or unveoscleral pathway in the
observed elevated IOP in RhoAV14-expressing rats. Like-
wise, the question of whether AH production by the ciliary
epithelium is inﬂuenced by Rho GTPase activation remains
open because we documented expression of recombinant
RhoAV14 in the ciliary muscle.
Consistent with Rho GTPase-induced OHT in rats
(Figure 2), topical application of Rho kinase inhibitor
(Y27632) decreased elevated IOP in the RhoAV14-expressing
rats. Treatment of RhoAV14-expressing rats with topical Rho
kinase inhibitor was found to be associated not only with
normal histology in the AH outﬂow pathway but also com-
parable levels of a-SMA, collagen-1A, and total collagen in
the AH outﬂow pathway relative to GFP-expressing controls.
These observations reveal that the Rho kinase inhibitor sup-
presses RhoAV14-induced ﬁbrogenic activity in the AH
outﬂow pathway. This set of results is also consistent with our
previous observations that used human TM cells in which both
Rho kinase inhibitor (Y27632) and pirfenidone, a known
antiﬁbrotic agent, decreased expression of a-SMA, collagen-
1A, and total collagen in the presence of TGF-b2.30 More-
over, Rho kinase inhibitors and statins that mimic Rho kinase
inhibitor responses were found to suppress ﬁbrosis in various
organs and tissues.31,58,64e68 Therefore, it is most likely that
the known ocular hypotensive effects of the Rho kinase in-
hibitors are related partly to their antiﬁbrogenic activity in
addition to their possible inﬂuence on cellular relaxation and
paracellular permeability through the inner wall of SC.45
Likewise, Rho kinase inhibitors are also known to suppress
the ﬁbrogenic activity of TGF-b, lysophoshatidic acid,
endothelin-1, and CTGF in different cell types.30,31,58,64e68
Each of these factors was also conﬁrmed to increase resis-
tance to AH outﬂow through the TM.19,23,26,69
Elevated Levels of Collagen in the AH Outﬂow Pathway
and Glaucoma
Finally, in support of our observations documented in the live
rat, in whichwe found a good correlation between elevated IOP
and ﬁbrogenic activity induced by RhoAV14, our analyses of
human autopsy glaucoma eyes provided evidence for signiﬁ-
cantly increased collagen-1A and total collagen in the TM,ajp.amjpathol.org - The American Journal of Pathology
RhoA-Induced Ocular Hypertension in RatsJCT, and SC areas in glaucomatous eyes compared with the
age-matched nonglaucomatous controls, implying a plausible
association between augmented ﬁbrogenic activity in the AH
outﬂow pathway and POAG. To our surprise and contrary to
the general thought,8,10,18 the accumulation of collagen-1A and
total collagen was found to be much higher in the TM (both
CS-TM and US-TM regions) compared with the JCT and SC.
Because we found a good match between the glaucoma spec-
imens and the nonglaucoma control specimens with respect to
age, sex, and race, we do not suspect that any of these factors
contributed to the increased accumulation of collagen in the
AH outﬂow pathway. These observations provide a signiﬁcant
insight into the potential role of accumulation of ECM in the
glaucoma specimens and its presumed involvement in
increased resistance to AH outﬂow and OHT.18
Conclusion
This study provides experimental evidence for increased
ﬁbrogenic activity because of dysregulated RhoA GTPase
activity in the trabecular AH outﬂow pathway leading to
increased IOP. Inhibition of Rho kinase prevents the ﬁbro-
genic response in a live OHT rodent model, further sup-
porting the importance of targeting the Rho/Rho kinase
signaling pathway for lowering IOP in glaucoma patients.
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